严重药品不良反应少见在婴儿某些治疗血管性肿瘤

Sorilla猎物,医学博士,of the Université de Bordeaux, France and colleagues examined the safety of propranolol therapy in treating infantile hemangioma, a vascular tumor characterized by rapid growth during the first weeks of life. Severe forms require systemic therapy. Propranolol, a beta blocker, induces regression, but safety data have been lacking for children. The study appears in the January 26 issue of《美国医学会杂志》。

孩子们与增生性小儿血管瘤需要整个法国系统性治疗对危及生命的(即。,potential airway obstruction) or functional risks or severe ulceration were referred to specialist centers for compassionate use of pediatric oral propranolol. Analyses involved data collected between April 2010 and April 2013. Adverse drug reactions (ADRs) were collected by questioning parents and reviewing the child health record at each monthly visit for up to 2 years.

922年病人提到,906年与普萘洛尔治疗,平均年龄约为4个月。的922患者中,81例(8.8%)有133美国存托凭证,包括24(2.6%)与36严重的药物不良反应。最常报道的adr是呼吸系统疾病(主要是感染),据报道在31日患者(6例严重的adr与普萘洛尔)。最严重的adr是心脏和代谢紊乱。

“开处方者必须建议父母在每个后续访问中断普萘洛尔在禁食和并发疾病,特别是在设置限制口服摄入和呼吸道症状,”作者写道。